MNK

ETC-206 is a selective inhibitor of MNK1 and MNK2 (IC50s: 64 nM and 86 nM).

HSND80 (Compound 1) is an orally active MNK/p70S6K inhibitor, exhibiting a Kd value of 44 nM for MNK1 and 4 nM for MNK2. The residence time of HSND80 on MNK1 and MNK2 is 45 minutes and 58 minutes, respectively. HSND80 effectively inhibits non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppresses the growth of triple-negative breast cancer (TNBC) cells in vitro.

MNK-IN-4 (compound D25) is a potent and selective MNK inhibitor used in treating acute spleen injury related to sepsis.

NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC₅₀ of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.

CGP 57380 (MNK1 Inhibitor) is a potent MNK1 inhibitor with IC50 of 2.2 μM, exhibiting no inhibitory activity on p38, JNK1, ERK1 and -2, PKC, or c-Src-like

Tomivosertib (eFT508) is a potent, highly selective MNK1 and MNK2 inhibitor with IC50 value of 1-2 nM.

Tomivosertib (eFT508) is a MNK1/2 inhibitor that blocks eIF4E phosphorylation, hindering tumor growth and immune signaling.

SLV-2436 (SEL201-88) is a novel effective and ATP-competitive inhibitor of MNK1 and MNK2 (IC50: 10.8/5.4 nM).

HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).

ETC-168 is a selective, orally active MNK inhibitor with IC50 values of 23 nM for MNK1 and 43 nM for MNK2. It demonstrates antiproliferative efficacy both in vivo and in vitro [1].

MNK1/2-IN-5 is a potent and selective MNK1/2 inhibitor with anticancer activity and can be used to study solid tumors and hematological malignancies.

DS12881479 can be used in cancer research which is a potent and selective inhibitor of Mnk1(IC 50 =21 nM) [1].

MNK inhibitor 9 potently blocks MNK1/2 (IC50: 0.003 µM each), is cell-permeable, and useful for tumor research.

HD202A is an orally active, selective dual inhibitor of MNK1/MNK2 (with IC50 values of 6.09 nM and 8.06 nM, respectively; Kd values of 1.913 μM and 5.244 μM, respectively), and it inhibits the MNK-eIF4E signaling pathway. By downregulating perilipin 2 and SCD1 while upregulating adipose triglyceride lipase and PPARγ coactivator 1α, HD202A enhances mitochondrial fatty acid oxidation and redox homeostasis. This compound effectively curtails weight gain, hepatic lipid accumulation, and elevated serum lipid levels, while significantly improving glucose tolerance and insulin sensitivity, and reducing inflammatory characteristics. HD202A shows significant potential for research applications in metabolic dysfunction-associated fatty liver disease.

MNK-IN-5 is an MNK inhibitor that suppresses MNK activity.

MNK-IN-6 (compound 1) is an inhibitor of MNK, and it is applicable for research in neuropathic pain.